Business ❯Pharmaceutical Industry ❯Market Dynamics
Novo Nordisk and Eli Lilly
The FDA's expanded approval of Wegovy for cardiovascular benefits in obese adults doesn't guarantee broader insurance coverage due to cost concerns.
